385 related articles for article (PubMed ID: 19898267)
1. The future of inflammatory bowel disease care.
Sandborn WJ
Rev Gastroenterol Disord; 2009; 9(3):E69-77. PubMed ID: 19898267
[TBL] [Abstract][Full Text] [Related]
2. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
3. Medical therapy of IBD in 2009.
Harris A; Feller ER; Shah SA
Med Health R I; 2009 Mar; 92(3):78-81. PubMed ID: 19385382
[No Abstract] [Full Text] [Related]
4. General principles of medical therapy of inflammatory bowel disease.
Friedman S
Gastroenterol Clin North Am; 2004 Jun; 33(2):191-208, viii. PubMed ID: 15177534
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of chronic inflammatory bowel diseases].
Lémann M
Bull Acad Natl Med; 2007 Jun; 191(6):1125-41; discussion 1141. PubMed ID: 18402168
[TBL] [Abstract][Full Text] [Related]
6. Medical management of the pregnant patient with inflammatory bowel disease.
Steinlauf AF; Present DH
Gastroenterol Clin North Am; 2004 Jun; 33(2):361-85, xi. PubMed ID: 15177544
[TBL] [Abstract][Full Text] [Related]
7. Update on pregnancy and breastfeeding in the era of biologics.
Yarur A; Kane SV
Dig Liver Dis; 2013 Oct; 45(10):787-94. PubMed ID: 23474350
[TBL] [Abstract][Full Text] [Related]
8. Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update.
Leso V; Leggio L; Armuzzi A; Gasbarrini G; Gasbarrini A; Addolorato G
Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):779-86. PubMed ID: 19786877
[TBL] [Abstract][Full Text] [Related]
9. [Current status of new drug development for inflammatory bowel diseases].
Kohgo Y; Tanabe H; Fujiya M
Nihon Rinsho; 2012 Feb; 70 Suppl 1():378-82. PubMed ID: 23126121
[No Abstract] [Full Text] [Related]
10. The use of biologic agents in pregnancy and breastfeeding.
Horst S; Kane S
Gastroenterol Clin North Am; 2014 Sep; 43(3):495-508. PubMed ID: 25110255
[TBL] [Abstract][Full Text] [Related]
11. Letter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure.
Macaluso FS; Criscuoli V; Orlando E; Rizzuto G; Renna S; Cottone M; Orlando A
Aliment Pharmacol Ther; 2016 May; 43(9):1019-20. PubMed ID: 27040168
[No Abstract] [Full Text] [Related]
12. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
Peyrin-Biroulet L
Minerva Gastroenterol Dietol; 2010 Jun; 56(2):233-43. PubMed ID: 20485259
[TBL] [Abstract][Full Text] [Related]
13. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
D'Haens GR; Panaccione R; Higgins PD; Vermeire S; Gassull M; Chowers Y; Hanauer SB; Herfarth H; Hommes DW; Kamm M; Löfberg R; Quary A; Sands B; Sood A; Watermeyer G; Lashner B; Lémann M; Plevy S; Reinisch W; Schreiber S; Siegel C; Targan S; Watanabe M; Feagan B; Sandborn WJ; Colombel JF; Travis S
Am J Gastroenterol; 2011 Feb; 106(2):199-212; quiz 213. PubMed ID: 21045814
[TBL] [Abstract][Full Text] [Related]
14. Letter: tumour necrosis factor alpha blocker switching--a not so simple pharmacokinetic.
Licinio R; Losurdo G; Ierardi E; Di Leo A; Principi M
Aliment Pharmacol Ther; 2015 Jun; 41(12):1302. PubMed ID: 25968153
[No Abstract] [Full Text] [Related]
15. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
16. Letter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure--authors' reply.
Gisbert JP; Chaparro M
Aliment Pharmacol Ther; 2016 May; 43(9):1020. PubMed ID: 27040169
[No Abstract] [Full Text] [Related]
17. Letter: tumour necrosis factor alpha blocker switching--a not so simple pharmacokinetic. Authors' reply.
Gisbert JP; Chaparro M
Aliment Pharmacol Ther; 2015 Jun; 41(12):1302-3. PubMed ID: 25968154
[No Abstract] [Full Text] [Related]
18. Inflammatory bowel disease.
Podolsky DK
N Engl J Med; 2002 Aug; 347(6):417-29. PubMed ID: 12167685
[No Abstract] [Full Text] [Related]
19. Mucosal healing with anti-TNF antibodies.
Chevaux JB; Vavricka SR; Rogler G; Lakatos PL; Schoepfer A; Peyrin-Biroulet L
Digestion; 2012; 86 Suppl 1():16-22. PubMed ID: 23051722
[TBL] [Abstract][Full Text] [Related]
20. Anti-TNF-alpha treatment strategies: results and clinical perspectives.
D'Haens G
Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S209-16. PubMed ID: 20117344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
